8-K filing — INCYTE CORP (INCY)
Filed: 2026-11-13 AccNo: 0000879169-26-000068 Size: 135 KB Item 8.01: Other Events
Stocks · News reference
Incyte has selected the University of Maryland School of Medicine and the H. Lee Moffitt Cancer Center & Research Institute as the recipients of its 2026 Incyte Ingenuity Awards in GVHD.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-13 AccNo: 0000879169-26-000068 Size: 135 KB Item 8.01: Other Events
Natera and Incyte have entered into a clinical collaboration agreement to evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in a new Phase II study for patients with stage 2/3 colorectal cancer.
Incyte's net sales guidance for Opzelura includes a one-time $246 million financial benefit resulting from a settlement with the Centers for Medicare and Medicaid Services (CMS).
Leerink Partners has revised its price target for Incyte Corporation from $154 to $150.
Incyte announced it will present new clinical data regarding its hematology portfolio at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition.